Larvol Delta - BIAL-RampD-Announces-First-Patient-Dosed-in-its-Phase-2-Clinical-Trial-of-BIA-286156-to-Treat-Parkinson39s-Disease-Patients-With-a-Pathogenic-Variant-in-the-Glucocerebrosidase-GBA1-Gene

BIA 28-6156 - BIAL

https://www.prnewswire.com/news-releases/bial-rd-announces-first-patient-dosed-in-its-phase-2-clinical-trial-of-bia-28-6156-to-treat-parkinsons-disease-patients-with-a-pathogenic-variant-in-the-glucocerebrosidase-gba1-gene-301833969.html

May 25, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next